We are committed to creating value for our society and our shareholders through life-changing peptide therapeutics for people who need them.

  • Shareholder portal
    • Share price information

      ZEAL (COP)


      Zealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL. Access investor information including full share price in DKK plus investor tools.

      More Stock information
    • Annual report 2023

      ZPAR23 Fullpage Images Firefly Copy

      2023 was an extraordinary year for Zealand Pharma and we delivered on key strategic objectives.

      Download PDF
    • Corporate presentation

      Crosby CHI NJ USA JW 0875 B3A6034

      See Zealand Pharma's latest Corporate Presentation highlighting our R&D pipeline and additional company information.

      Download PDF


      of our operating expenditure focused on R&D in 2023


      analysts covering Zealand Pharma


      shares outstanding as of March 31, 2024


      employees in Denmark and the United States

    Upcoming events

    See all Events
    Zealand Pharm Office Part 1 BF3I0028 2

    Catch up on our past events

    View the webcasts and documents from our past events here

    Past events

    Q1 2024 Interim Report

    Latest financial report

    On May 16, 2024, Zealand Pharma reported interim results for the quarter ended March 31, 2024 and provided a company update.

  • Download PDF
  • All financial reports
  • Zealand Pharma 0425

    Latest news


      Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants


      Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis


      Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL


      Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency

    Zealand Pharma 1503

    Stay up-to-date with the latest news from Zealand

    Sign up to receive press releases and important company announcements directly to your inbox


    Financial calendar

    See all financial events
    • Corporate governance

      At Zealand Pharma, our corporate governance structure aims to support long-term financial performance, meet the obligations of our stakeholders, and create value for shareholders and society.

    • Annual general meeting

      The Annual General Meeting for 2024 was held on Wednesday, March 20th, 2024 at 15:00 CET. Find additional information and the webcast recording on the AGM page.

    • Analyst coverage

      Zealand Pharma is currently covered by 10 analysts and financial institutions across the U.S and Europe.

    Safety, tolerability, and clinical effects of ZP8396, an amylin analog

    Featured publications

    Results from a 6-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in October 2024.

  • Read publication
  • All scientific publications
  • Zealand Pharma 0682

    An innovative R&D pipeline



    A long-acting amylin analog as a weight-loss medication representing an alternative to GLP-1 receptor agonists.



    A long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation.



    A long-acting glucagon/GLP-1 receptor dual agonist targeting obesity and MASH licensed to Boehringer Ingelheim.



    A GIP receptor agonist targeting obesity as a potential complement to GLP-1 for increased effect and/or tolerability.

    Congenital Hyperinsulinism

    Dasiglucagon: Continuous infusion

    A glucagon analog designed to allow for continuous subcutaneous infusion via a wearable pump system for the treatment of Congenital Hyperinsulinism (CHI).

    Short Bowel Syndrome


    A long-acting GLP-2 analog designed to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure.

    Chronic inflammation


    A potent and selective blocker of the Kv1.3 ion channel with the potential to treat a broad range of T-cell-driven autoimmune diseases.

    Chronic inflammation


    A long-acting inhibitor of the Complement C3 protein with the potential to target a broad range of complement-mediated diseases.

    Type 1 diabetes

    Dasiglucagon: Diabetes

    A glucagon analog with potential for use in Bihormonal Pancreas systems with insulin for the treatment of Type 1 diabetes

    More investor information

    Investor relations policy

    We are committed to providing reliable and transparent information about our business, development programs and scientific results in a clear and timely manner.

  • Find our IR Policy
  • Prospectus

    Read our latest prospectus and prospectus summary from April 3, 2023.

  • Download prospectus summary
  • Download prospectus
  • Investor and Media contacts

    • Anna ALR0858

      Anna Krassowska

      Vice President, Investor Relations & Corporate Communications

      Email Anna